(2022). A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
A Randomized, Open-label Trial of Combined Nitazoxanide and Atazanavir/ritonavir for Mild to Moderate COVID-19. 2022.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
A Randomized, Open-label Trial of Combined Nitazoxanide and Atazanavir/ritonavir for Mild to Moderate COVID-19. 2022.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.